Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has been given an average rating of “Buy” by the seven analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $5.18.
Several equities research analysts have commented on the company. Zacks Investment Research downgraded Catabasis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 29th. Wedbush boosted their target price on Catabasis Pharmaceuticals from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Tuesday, March 20th.
A number of institutional investors have recently added to or reduced their stakes in CATB. Renaissance Technologies LLC boosted its holdings in Catabasis Pharmaceuticals by 167.2% in the fourth quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock worth $698,000 after acquiring an additional 293,300 shares in the last quarter. Deutsche Bank AG bought a new stake in Catabasis Pharmaceuticals in the fourth quarter worth $335,000. Finally, Geode Capital Management LLC boosted its holdings in Catabasis Pharmaceuticals by 146.1% in the fourth quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock worth $114,000 after acquiring an additional 45,476 shares in the last quarter. 27.94% of the stock is currently owned by institutional investors and hedge funds.
Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.31) by $0.07. The firm had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.25 million. equities research analysts predict that Catabasis Pharmaceuticals will post -0.92 earnings per share for the current year.
WARNING: This story was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.chaffeybreeze.com/2018/04/16/catabasis-pharmaceuticals-inc-catb-given-average-rating-of-buy-by-analysts.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.